This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

William Winston, Ph.D.
Vice President, Research at Werewolf Therapeutics

Profile

Dr. Bill Winston is an expert protein engineer with deep experience in the design, discovery, and preclinical development of therapeutic antibody treatments. Most recently, Dr. Winston served as Senior Director, then Vice President of Antibody Development at Potenza Therapeutics. With Potenza, he led both internal and external efforts to identify and, in partnership with Astellas, manage the contract manufacturing of a portfolio of three monoclonal antibodies that all successfully achieved IND clearances prior to the Company’s acquisition by Astellas Pharmaceuticals in 2018. Before joining Potenza, Dr. Winston was a key discovery scientist at AVEO Oncology.

Dr. Winston is a graduate of the Massachusetts Institute of Technology where he earned a B.S. in Biology, and he holds a Ph.D. in Biology from Harvard.

Agenda Sessions

  • Engineering Novel Conditionally Activated Immune Therapeutics to Fight Cancer

    On Demand
  • Inducible Activation of Antibodies to Enhance Therapeutic Index

    3:30pm